| Class / Patent application number | Description | Number of patent applications / Date published |
|---|
| 514395000 | Chalcogen or nitrogen bonded directly at 1-, 2- or 3-position of the diazole ring by nonionic bonding | 35 |
| 20080200529 | Novel 2-Amino Benzimidazole Derivatives and Their Use As Modulators Of Small-Conductance Calcium-Activated Potassium Channels - This invention relates to novel 2-amino benzimidazole derivatives useful as modulators of small-conductance calcium-activated potassium channels (SK channels). | 08-21-2008 |
| 20080293796 | Parenteral and oral formulations of benzimidazoles - Provided herein are drug delivery systems comprising nanosuspension formulations suitable for parenteral delivery to a subject. The nanosuspension formulations may comprise a benzimidazole derivative, e.g., mebendazole, and surface stabilizers, such as block copolymer(s), e.g., Pluronic F108, and surfactant(s), e.g., Tween 80, and, optionally, water. Provided are methods for defining nanosuspensions of a benzimidazole derivative as having maximum therapeutic efficacy for a treatment regimen by adjusting and/or selecting particles size(s) based on pharmacokinetic parameters of the derivative in the tissue. Also provided are methods for improving the bioavailability of a benzimidazole derivative during treatment of a pathophysiological condition and for treating a cancer by using formulation(s) combining particle diameters whereby the retention of the benzimidazole derivative within the particles increases as the diameter increases such that, upon administration, release of the benzimidazole derivative from the particles into tissue is continuous over a range of time as determined by the particle diameters. | 11-27-2008 |
| 20090023792 | INHIBITORS OF MELANOCYTE TYROSINASE AS TOPICAL SKIN LIGHTENERS - Methods and formulations are provided to reduce pigmentation in skin, using an array of compounds selected from benzimidazoles, phenylthioureas, phenyltiols, phenylamines, bi- and multicyclic phenols, thiopheneamines, and benzothiamides. The compounds preferably inhibit pigment systhesis in melanocytes through the tyrosinase pathway. The methods can be used for lightening skin, and for treating uneven skin complexions which result from hyperpigmentation-related medical conditions such as melasma, age spots, freckles, ochronosis, and lentigo. The compounds can be used medically or cosmetically. | 01-22-2009 |
| 20090023793 | INHIBITORS OF MELANOCYTE TYROSINASE AS TOPICAL SKIN LIGHTENERS - Methods and formulations are provided to reduce pigmentation in skin, using an array of compounds selected from benzimidazoles, phenylthioureas, phenyltiols, phenylamines, bi- and multicyclic phenols, thiopheneamines, and benzothiamides. The compounds preferably inhibit pigment systhesis in melanocytes through the tyrosinase pathway. The methods can be used for lightening skin, and for treating uneven skin complexions which result from hyperpigmentation-related medical conditions such as melasma, age spots, freckles, ochronosis, and lentigo. The compounds can be used medically or cosmetically. | 01-22-2009 |
| 20090048322 | Parenteral and oral formulations of benzimidazoles - Provided herein are drug delivery systems, such as self-nanoemulsifying drug delivery systems, self-emulsifying drug delivery systems and parenteral microemulsion formulations, suitable for parenteral or oral delivery to a subject. The drug delivery systems may comprise a benzimidazole derivative, e.g., mebendazole, an oil, a surfactant, a cosurfactant and a dipolar aprotic solvent in a microemulsion formulation. Also provided are methods for improving the bioavailability of a benzimidazole derivative during treatment of a pathophysiological condition by using a formulation combining a particular emulsion droplet diameter and ratio of the surfactant:cosurfactant therein, for increasing concentration and retention of a benzimidazole derivative in the lung via a parenterally administerable microemulsion with droplet size of about 35 nm to less than 100 nm and for defining hemolytically safe microemulsions of a benzimidazole derivative during a therapeutic treatment via a parenterally administerable microemulsion with a surfactant:cosurfactant content by weight of about 6% to 48%. | 02-19-2009 |
| 20090054507 | CONTROL OF MALIGNANT CELLS BY KINASE INHIBITION - Inhibitors of casein kinase 2 are described that have been found to arrest uncontrolled cell proliferation, thereby suggesting their use in cancer treatment strategies. Specific applications include treating breast cancer, colon cancer, melanoma, chronic myelogenous leukemia, bladder cancer, renal cancer, and brain cancer. Various methods and compositions utilizing the inhibitors are described. | 02-26-2009 |
| 20090076106 | 2-(Phenylamino) Benzimidazole Derivatives and Their Use as Modulators of Small- Conductance Calcuim-Activated Potassium Channels - This invention relates to novel 2-(phenylamino)benzimidazole derivatives useful as modulators of small-conductance calcium-activated potassium channels (SK channels). | 03-19-2009 |
| 20090239921 | METHODS FOR TREATING NEOPLASMS WITH DERIVATIVES OF 4,5,6,7-TETRABROMOBENZIMIDAZOLE - A pharmaceutical composition exhibiting an anti-neoplastic activity, comprising: a pharmaceutically-effective amount of a compound of Formula 1 | 09-24-2009 |
| 20100029736 | 2-SUBSTITUTED PROLINE BIS-AMIDE OREXIN RECEPTOR ANTAGONISTS - The present invention is directed to 2-substituted proline bis-amide compounds which are antagonists of orexin receptors, and which are useful in the treatment or prevention of neurological and psychiatric disorders and diseases in which orexin receptors are involved. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which orexin receptors are involved. | 02-04-2010 |
| 20100035951 | 2-AMINO BENZIMIDAZOLE DERIVATIVES AND THEIR USE AS MODULATORS OF SMALL-CONDUCTANCE CALCIUM-ACTIVATED POTASSIUM CHANNELS - This invention relates to 2-amino benzimidazole derivatives of Formula 1a or 1b: | 02-11-2010 |
| 20100048658 | FUSED HETEROCYCLIC COMPOUNDS - There is provided a compound of the formula: | 02-25-2010 |
| 20100105749 | CHEMICAL COMPOUNDS, PHARMACEUTICAL COMPOSITIONS AND METHODS - The present invention provides compounds of the formulae (I) and (II), and derivatives thereof, for the treatment of cardiovascular conditions | 04-29-2010 |
| 20100113548 | ANTAGONISTS OF BITTER TASTE RECEPTORS AND USES THEREOF - The present invention relates to antagonists of the human bitter-taste receptors hTAS2R38. The invention also relates to methods for identifying further molecules that suppress hTAS2R38 mediated bitter taste transduction or bitter taste response and uses thereof. | 05-06-2010 |
| 20100168196 | N-Substituted (Benzoimidazol-2-yl)phenylamines, Processes for Their Preparation, Their Use as a Medicament or Diagnostic Aid, and a Medicament Comprising Them - This invention is directed to the compound of formula (I), compositions containing said compounds to inhibit the sodium-proton exchanger of subtype 3 (NHE3) which are useful in the prevention or treatment of various disorders in a patient suffering from a disease state, such as, renal disorders including acute or chronic renal failure, disorders of biliary function and for respiratory disorders such as snoring or sleep apnea or for stroke. | 07-01-2010 |
| 20100286220 | HNF4alpha ANTAGONISTS AND METHODS OF USE - Disclosed are methods and compositions relating to antagonists of HNF4α. | 11-11-2010 |
| 20100317706 | HNF4alpha MODULATORS AND METHODS OF USE - Disclosed are methods and compositions relating to modulators, such as agonists and antagonists, of HNF4α. | 12-16-2010 |
| 20110034528 | Elansolids, Novel Natural Metabolites of Flexibacter and Antibiotically Active Derivatives Thereof - The present invention describes Elansolids, a new class of novel anti-bacterial compounds of formula (I). | 02-10-2011 |
| 20110082182 | THERAPEUTIC ANTIVIRAL PEPTIDES - Disclosed herein are compounds represented by a formula: | 04-07-2011 |
| 20110288139 | SUBSTITUTED AMINO-BENZIMIDAZOLES, MEDICAMENTS COMPRIMISING SAID COMPOUND, THEIR USE AND THEIR METHOD OF MANUFACTURE - The present invention relates to substituted amino-benzimidazoles of general formula (1) wherein the groups R | 11-24-2011 |
| 20120046329 | MODULATORS OF NOD1 AND NOD2 SIGNALING, METHODS OF IDENTIFYING MODULATORS OF NOD1 AND NOD2 SIGNALING, AND USES THEREOF - Disclosed herein are compositions and methods relating to modulators of Nod-like Receptors NOD1 (NLRC1) and NOD2 (NLRC2) signaling. Further provided are methods of identifying modulators of Nod-like Receptors NOD1 and NOD2 activity. Further provided are compositions and methods for treating or preventing inflammation, including diseases associated with inflammation such as inflammatory bowel diseases (Crohn's disease, ulcerative colitis), pancreatitis, arthritis, asthma, psoriasis. Alzheimer's disease, cardiovascular disease (arteritis), diabetes, and sepsis. | 02-23-2012 |
| 20120178785 | DERIVATIVES OF N-PHENYLANTHRANILIC ACID AND 2-BENZIMIDAZOLONE AS POTASSIUM CHANNEL AND/OR NEURON ACTIVITY MODULATORS - Compounds, compositions and methods are provided which are useful in the treatment of conditions such as central or peripheral nervous system disorders through the modulation of potassium ion flux through voltage-dependent potassium channels and/or depressing cortical and/or peripheral neuron activity are disclosed. Novel derivatives of N-phenylanthranilic acid are also disclosed. | 07-12-2012 |
| 20120214856 | TREATMENT FOR CANCER - The present invention provides methods for the treatment of tumors, comprising administration of an effective amount of at least one taxoid and an effective amount of at least one benzimidazol carbamate compound of formula (I). The invention also provides a method for the treatment of tumors insensitive to one or more anti-mitotic drugs, the method comprising administering a effective amount of at least one benzimidazole carbamate compound of formula (I). Also provide are compositions for carrying out methods of the invention. | 08-23-2012 |
| 20140031403 | Solid Forms of Curcumin - The present invention provides forms of curcumin and the pharmaceutical compositions thereof. The forms of curcumin disclosed herein are curcumin polymorph Form III, curcumin-2-aminobenzimidazole co-crystal, and curcumin-L-lysine co-crystal. Further, the invention provides methods inhibiting cancer cells and HSV-1 using these curcumin novel solid forms. | 01-30-2014 |
| 20140045909 | DENIBULIN DI-HYDROCHLORIDE - MN-029 di-hydrochloride (MN-029.2HCl, Formula 2) is a potent vascular targeting agent. | 02-13-2014 |
| 20140249196 | N-BENZYLBENZIMIDAZOLE MODULATORS OF PPARG - The invention provides molecular entities that bind with high affinity to PPARG (PPARγ), inhibit cdk5-mediated phosphorylation of PPARG, but do not exert an agonistic effect on PPARG. Compounds of the invention can be used for treatment of conditions in patients wherein PPARG plays a role, such as diabetes or obesity. Methods of preparation of the compounds, bioassay methods for evaluating compounds of the invention as non-agonistic PPARG binding compounds, and pharmaceutical compositions are also provided. | 09-04-2014 |
| 20140329873 | Meglumine salt formulations of 1-(5,6-dichloro-1H-benzo[D]imidazol-2-yl)-1H-pyrazole-4-carboxylic acid - The meglumine salt of 1-(5,6-dichloro-1H-benzo[d]imidazol-2-yl)-1H-pyrazole-4-carboxylic acid (compound (1)) and pharmaceutically acceptable formulations thereof are described. Such compounds may be used in pharmaceutical compositions and methods for the treatment of disease states, disorders, and conditions mediated by prolyl hydroxylase activity. | 11-06-2014 |
| 20150011599 | THICKENING COMPOSITION FOR USE IN AGROCHEMICAL FORMULATIONS, USE OF A THICKENING COMPOSITION AND AGROCHEMICAL FORMULATIONS CONTAINING A THICKENING COMPOSITION - The present invention describes a novel thickening composition that comprises a mixture of esters of an alkoxylated polyol and is used to enhance the viscosity of agrochemical formulations. The composition according to the present invention may present itself in solid for or in liquid form, in this latter case further comprising one or more surfactants, solvents, and optionally water. The thickening composition described in this invention is compatible with a large variety of pesticides and inert components used in agrochemical formulations, and it has evidence that it is capable of improving the stability and the effectiveness of the said formulations. | 01-08-2015 |
| 20150011600 | NOVEL BENZIMIDAZOLE DERIVATIVE AND USE THEREOF - The present invention aims to provide a compound capable of inhibiting PCA-1 that can be a target for a novel treatment method of various diseases, and pharmaceutical use of the compound. A compound represented by the formula (I): | 01-08-2015 |
| 20160130222 | INHIBITORS OF THE MITF MOLECULAR PATHWAY - Provided herein are compounds of the formula (IV) as well as pharmaceutically acceptable salts thereof, wherein the substituents are as those disclosed in the specification. These compounds, and the pharmaceutical compositions containing them, are useful as MITF inhibitors, MITF pathway inhibitors and for the treatment of cancer. | 05-12-2016 |
| 20160130234 | PHARMACEUTICAL COMPOSITIONS BASED ON PHOTOCHEMICALLY STABLE SILVER COMPLEXES, CHLOREXIDINE AND CATIONIC SURFACTANTS - The present invention generally relates to silver complexes of formula (I) and (II), having high stability and showing antimicrobial activity. The invention also relies on compositions containing said photochemically stable silver complexes of formula (I) and (II), optionally admixed with at least another antimicrobial agent, thus enhancing their antimicrobic activity. | 05-12-2016 |
| 20160168127 | BENZOIMIDAZOLES AS PROLYL HYDROXYLASE INHIBITORS | 06-16-2016 |
| 20160251317 | PARASITICIDAL COMPOSITIONS COMPRISING BENZIMIDAZOLE DERIVATIVES, METHODS AND USES THEREOF | 09-01-2016 |
| 20170231962 | Compound Combinations for Attenuation of Bacterial Virulence | 08-17-2017 |
| 20170231964 | PHARMACEUTICAL COMPOSITIONS DIRECTLY TARGETING FKBP52 FOR THE TREATMENT OF PROSTATE CANCER AND METHODS OF USING SAME | 08-17-2017 |
| 20180022733 | BENZOIMIDAZOLES AS PROLYL HYDROXYLASE INHIBITORS | 01-25-2018 |
